New Phase 1 Data for OTX-TKI

Andrew Moshfeghi, MD

Show Description +

Andrew Moshfeghi, MD, discusses 10-month data from the phase 1 study of intravitreal axitinib implant (Ocular Therapeutix) for wet AMD.

Posted: 5/15/2023

Keywords:

axitinib implant

•

Wet AMD

•

retina-meeting-recap

•

Clinical Trials

Up Next

Name: New Phase 1 Data for OTX-TKI
Uploaded: 2023-05-15T17:17:51+00:00
Description: Andrew Moshfeghi, MD, discusses 10-month data from the phase 1 study of intravitreal axitinib implant (Ocular Therapeutix) for wet AMD.

Reducing AMD Risk with Metformin

Neal Peachey, PhD

The Value of Multimodal Imaging in Diabetic Retinopathy

Stela Vujosevic, MD, PhD, FARVO, FEBO

The Risk of iRORA Revealed

Hanna Choi, BS

Tackling the Diabetic Retinopathy "Pandemic"

Tien Yin Wong, MBBS, MMED (Ophth), MPH, PhD

DAVIO Trial Updates

Ashkan M. Abbey, MD

The Latest From LIGHTSITE III

Marion R. Munk, MD, PhD

A Look at Visual Outcomes in GATHER2

Carl Danzig, MD

Back to All Videos

New Phase 1 Data for OTX-TKI

Andrew Moshfeghi, MD

Andrew Moshfeghi, MD, discusses 10-month data from the phase 1 study of intravitreal axitinib implant (Ocular Therapeutix) for wet AMD.

Posted: 5/15/2023

Keywords:

axitinib implant

•

Wet AMD

•

retina-meeting-recap

•

Clinical Trials

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

New Phase 1 Data for OTX-TKI

Up Next

New Phase 1 Data for OTX-TKI

More From ARVO: 2023 Coverage